Skip to Content

Eraxis Approval History

  • FDA approved: Yes (First approved February 17th, 2006)
  • Brand name: Eraxis
  • Generic name: anidulafungin
  • Dosage form: Injection
  • Company: Pfizer Inc.
  • Treatment for: Candidemia

Eraxis (anidulafungin) is an antifungal medicine of the echinocandin class, indicated for the treatment of candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis) and esophageal candidiasis.

Development History and FDA Approval Process for Eraxis

Feb 17, 2006Approval Eraxis - Pfizer Inc - Treatment for Candidemia
Aug 18, 2005Vicuron Pharmaceuticals Files New Drug Application (NDA) for Anidulafungin for Treatment of Invasive Candidiasis/Candidemia
May 31, 2005Vicuron Pharmaceuticals Files Amendment to Anidulafungin New Drug Application (NDA) for Treatment of Esophageal Candidiasis
Sep 21, 2004Vicuron Pharmaceuticals Provides Update on Anidulafungin Regulatory Paths
May 24, 2004Vicuron Pharmaceuticals Receives Approvable Letter from FDA for Anidulafungin for the Treatment of Esophageal Candidiasis Requesting Additional Data
Jan 22, 2004Vicuron Pharmaceuticals Announces 90-Day Extension of FDA Review of Anidulafungin New Drug Application

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.